13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • South Australia - Lung & mesothelioma

    Research> Current clinical trials> Lung & mesothelioma

    Every day researchers work towards finding new breakthroughs in cancer. Clinical trials play a pivotal role in bringing that defeat closer.

    Clinical trials test promising new treatments on people to see if they are better than existing cancer treatments. The trial process is long starting many years before an actual treatment can be used.

    By joining a clinical trial you are helping to create new breakthroughs in cancer research. Hundreds of thousands of people all over the world have taken part in clinical trials that have lead to safer and more effective treatments for many cancers.

    It is important to note that not all cancer patients are eligible to take part in clinical trials and there are not clinical trials for all types of cancer.

    You may decide to join a clinical trial because:

    • The treatment you receive will be at least the best available for your illness.
    • Your health may improve because of the treatment you receive.
    • You may receive a treatment you would not otherwise have access to.
    • Your health will be carefully checked by the treatment team running the trial.
    • You will be part of the worldwide effort to improve cancer treatment.

    For more information on clinical trials please click here.

    Clinical trial managers:

    If you would like information regarding any of the below clinical trials, please contact the appropriate Clinical trials manager:

    Ashford Cancer Centre: Helen Daykin, +61 8 8292 2240

    Flinders Medical Centre: Alex Scott-Hoy, +61 8 8204 4830

    The Queen Elizabeth:  Sue Yeend, +61 8 8222 6148

    Lyell McEwin Hospitals: Julie Rowe or Rohit Joshi +61 8 8282 0833

    Royal Adelaide Hospital: Anne Milton, +61 8 7074 2342

    Current clinical trials for lung & mesothelioma cancer

    Status Description Organisation
    Recruiting ADAURA A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA) Flinders Medical Centre
    Not Yet Recruiting Bayer Basket Study - Phase 1b basket study of anetumab ravansine in patients with mesothelin expressing advanced or recurrent solid tumours (TNBC/Thymic/Cholaniocarcinoma/pancrea tic adenocarcinoma) Flinders Medical Centre
    Recruiting BMS 227 An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer Lyell McEwin Hospital
    Recruiting BMS 384 A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks The Lyell McEwin Hospital
    Recruiting BR.31 A PHASE III PROSPECTIVE DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ADJUVANT MEDI4736 IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER Flinders Medical Centre
    Recruiting BR31 - A Phase III Prospective Double Blind Randomized Study Of Adjuvant Medi4736 in completely resected Non-Small Cell Lung Cancer Royal Adelaide Hospital
    Recruiting CA209-384 CHECKMATE A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240mg Every 2 Weeks vs Nivolumab 480mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received up to 12 Months of Nivolumab at 3mg/kg or 240mg Every 2 Weeks. Ashford Cancer Centre Research
    Recruiting CEFG816X2201C - A phase II, multicentre, parallel group open label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and INC280 in combination with Nivolumab in cMET positive adult patients with NSCLC Royal Adelaide Hospital
    Recruiting CheckMate 384 (Lung) A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks Flinders Medical Centre
    Recruiting Javelin lung 100. A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of recurrent or Stage IV PD-L1+ non small cell lung cancer. The Queen Elizabeth Hospital
    Recruiting KEYNOTE-604 A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK- 3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer The Lyell McEwin Hospital
    Mesothelioma QOL - An Observational Study of Health-related 413.14 Quality of Life in People with Malignant Mesothelioma Flinders Medical Centre
    Recruiting Mirati Lung Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor Flinders Medical Centre
    Not yet recruiting NIVORAD A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer progressing after first or second line chemotherapy Royal Adelaide Hospital
    Recruiting A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Flinders Medical Centre
    Recruiting TROG 11.03 - A Randomised Phase III Trials of High Dose Palliative Radiotherapy (HDPRT) versus Concurrent Chemotherapy + HDPRT (C-HDPRT) In patients with good performance status, locally Advanced / Small Volume Metastatic NSCLC not suitable for Radical Chemo-radiother Flinders Medical Centre
    Recruiting TROG 13.01 - A randomised phase 2 trial of stereotactic ablative fractionated radiotherapy versus radiosurgery for oligometastatic neoplasia to the lung Royal Adelaide Hospital

    Today at Cancer Council SA

  • Do you have a cancer question?

    Do you have a cancer question?

    Cancer causes questions. Call us for the answers.

  • Donations In Memoriam

    Donations In Memoriam

    Donating In Memoriam to Cancer Council SA can be a meaningful way for family, friends and loved ones to show support to the grieving, and to remember someone lost to cancer.

  • Fundraising events

    Fundraising events

    We have a wide range of exciting events that give you the opportunity to support our vision of a cancer free future in a fun, easy yet symbolic way.

  • Heard something about cancer and not sure if it's true?

    Heard something about cancer and not sure if it's true?

    Get all the evidence based answers to your cancer questions here.

  • Join the conversation

    Join the conversation

    Follow us on Facebook to stay up to date with the latest community events and news.

  • Quitline

    Quitline

    Quitline is a government-funded service operated by Cancer Council SA, with the sole goal of providing the support, strategies and information to empower individuals to quit smoking.